236 related articles for article (PubMed ID: 15353372)
41. Comparison of the computed structures for the phosphate-binding loop of the p21 protein containing the oncogenic site Gly 12 with the X-ray crystallographic structures for this region in the p21 protein and EFtu. A model for the structure of the p21 protein in its oncogenic form.
Chen JM; Lee G; Murphy RB; Carty RP; Brandt-Rauf PW; Friedman E; Pincus MR
J Biomol Struct Dyn; 1989 Apr; 6(5):859-75. PubMed ID: 2686707
[TBL] [Abstract][Full Text] [Related]
42. Site-specific phosphorylation of raf in cells containing oncogenic ras-p21 is likely mediated by jun-N-terminal kinase.
Adler V; Bowne W; Michl J; Sookraj KA; Ikram K; Pestka S; Izotova L; Zenilman M; Friedman FK; Qu Y; Pincus MR
Ann Clin Lab Sci; 2008; 38(1):47-56. PubMed ID: 18316782
[TBL] [Abstract][Full Text] [Related]
43. Molecular dynamics of the H-ras gene-encoded p21 protein; identification of flexible regions and possible effector domains.
Dykes DC; Friedman FK; Dykes SL; Murphy RB; Brandt-Rauf PW; Pincus MR
J Biomol Struct Dyn; 1993 Dec; 11(3):443-58. PubMed ID: 8129867
[TBL] [Abstract][Full Text] [Related]
44. Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-->Leu61).
Gedde-Dahl T; Spurkland A; Eriksen JA; Thorsby E; Gaudernack G
Int Immunol; 1992 Nov; 4(11):1331-7. PubMed ID: 1282032
[TBL] [Abstract][Full Text] [Related]
45. An effector peptide from glutathione-S-transferase-pi strongly and selectively blocks mitotic signaling by oncogenic ras-p21.
Chie L; Adler V; Friedman FK; Chung D; Pincus MR
Protein J; 2004 Apr; 23(3):235-8. PubMed ID: 15200055
[TBL] [Abstract][Full Text] [Related]
46. A novel potential effector of M-Ras and p21 Ras negatively regulates p21 Ras-mediated gene induction and cell growth.
Ehrhardt GR; Korherr C; Wieler JS; Knaus M; Schrader JW
Oncogene; 2001 Jan; 20(2):188-97. PubMed ID: 11313946
[TBL] [Abstract][Full Text] [Related]
47. Conformational transitions in p21ras and in its complexes with the effector protein Raf-RBD and the GTPase activating protein GAP.
Geyer M; Schweins T; Herrmann C; Prisner T; Wittinghofer A; Kalbitzer HR
Biochemistry; 1996 Aug; 35(32):10308-20. PubMed ID: 8756686
[TBL] [Abstract][Full Text] [Related]
48. Post-translational processing of purified human K-ras in Xenopus oocytes.
Kaplan JB; Sass PM
Cancer Commun; 1991; 3(12):383-8. PubMed ID: 16296004
[TBL] [Abstract][Full Text] [Related]
49. Evidence that oocyte maturation induced by an oncogenic ras-p21 protein and insulin is mediated by overlapping yet distinct mechanisms.
Chung DL; Joran A; Friedman F; Robinson R; Brandt-Rauf PW; Weinstein IB; Ronai Z; Baskin L; Dykes DC; Murphy RB
Exp Cell Res; 1992 Dec; 203(2):329-35. PubMed ID: 1459198
[TBL] [Abstract][Full Text] [Related]
50. Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules.
Krengel U; Schlichting I; Scherer A; Schumann R; Frech M; John J; Kabsch W; Pai EF; Wittinghofer A
Cell; 1990 Aug; 62(3):539-48. PubMed ID: 2199064
[TBL] [Abstract][Full Text] [Related]
51. Three-dimensional structure of p21H-ras and its implications.
Wittinghofer F
Semin Cancer Biol; 1992 Aug; 3(4):189-98. PubMed ID: 1421163
[TBL] [Abstract][Full Text] [Related]
52. Computed three-dimensional structures for the ras-binding domain of the raf-p74 protein complexed with ras-p21 and with its suppressor protein, rap-1A.
Chen JM; Manolatos S; Brandt-Rauf PW; Murphy RB; Monaco R; Pincus MR
J Protein Chem; 1996 Aug; 15(6):511-8. PubMed ID: 8895097
[TBL] [Abstract][Full Text] [Related]
53. Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function.
Hocker HJ; Cho KJ; Chen CY; Rambahal N; Sagineedu SR; Shaari K; Stanslas J; Hancock JF; Gorfe AA
Proc Natl Acad Sci U S A; 2013 Jun; 110(25):10201-6. PubMed ID: 23737504
[TBL] [Abstract][Full Text] [Related]
54. A peptide from a ras effector-domain blocks ras-dependent cardiac hypertrophy in myocytes.
Deng L; Boujdir M; Tremontano A; Pincus MR; El-Sherif N
Ann Clin Lab Sci; 2009; 39(4):351-60. PubMed ID: 19880762
[TBL] [Abstract][Full Text] [Related]
55. Ras regulatory interactions: novel targets for anti-cancer intervention?
Prendergast GC; Gibbs JB
Bioessays; 1994 Mar; 16(3):187-91. PubMed ID: 8166672
[TBL] [Abstract][Full Text] [Related]
56. Novel, provable algorithms for efficient ensemble-based computational protein design and their application to the redesign of the c-Raf-RBD:KRas protein-protein interface.
Lowegard AU; Frenkel MS; Holt GT; Jou JD; Ojewole AA; Donald BR
PLoS Comput Biol; 2020 Jun; 16(6):e1007447. PubMed ID: 32511232
[TBL] [Abstract][Full Text] [Related]
57. Allosteric effects of the oncogenic RasQ61L mutant on Raf-RBD.
Fetics SK; Guterres H; Kearney BM; Buhrman G; Ma B; Nussinov R; Mattos C
Structure; 2015 Mar; 23(3):505-516. PubMed ID: 25684575
[TBL] [Abstract][Full Text] [Related]
58. Glutathione-S-Transferase as a selective inhibitor of oncogenic ras-p21-induced mitogenic signaling through blockade of activation of jun by jun-N-terminal kinase.
Villafania A; Anwar K; Amar S; Chie L; Way D; Chung DL; Adler V; Ronai Z; Brandt-Rauf PW; Yamaizumii Z; Kung HF; Pincus MR
Ann Clin Lab Sci; 2000 Jan; 30(1):57-64. PubMed ID: 10678584
[TBL] [Abstract][Full Text] [Related]
59. Cloning of bovine GAP and its interaction with oncogenic ras p21.
Vogel US; Dixon RA; Schaber MD; Diehl RE; Marshall MS; Scolnick EM; Sigal IS; Gibbs JB
Nature; 1988 Sep; 335(6185):90-3. PubMed ID: 2842690
[TBL] [Abstract][Full Text] [Related]
60. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?
Nussinov R; Tsai CJ; Jang H
Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
